Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases
This article was originally published in The Pink Sheet Daily
Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.
You may also be interested in...
Infinity Gets More Than A Cash Boost With AbbVie Tie-Up
In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.
Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance
Infinity avoids the erosion of its rights to a promising PI3K drug by restructuring its alliance with Purdue and Mundipharma, essentially returning all control back to the cancer drug developer.
Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.